Loss of bone mineral density (BMD) due to androgen deprivation therapy

Loss of bone mineral density (BMD) due to androgen deprivation therapy refers to an iatrogenic skeletal complication predominantly affecting men undergoing systemic endocrine suppression—typically via GnRH analogs, antiandrogens, or bilateral orchiectomy—for prostate cancer Pathophysiologically, severe castrate levels of testosterone lead to an abrupt decline in both androgenic signaling and its aromatization into estrogens, which are essential for male skeletal homeostasis This hormone deficien...

Loss of bone mineral density (BMD) due to androgen deprivation therapy refers to an iatrogenic skeletal complication predominantly affecting men undergoing systemic endocrine suppression—typically via GnRH analogs, antiandrogens, or bilateral orchiectomy—for prostate cancer Pathophysiologically, severe castrate levels of testosterone lead to an abrupt decline in both androgenic signaling and its aromatization into estrogens, which are essential for male skeletal homeostasis

This hormone deficiency markedly upregulates osteoclastic bone resorption relative to osteoblastic bone formation, resulting in accelerated microarchitectural deterioration and rapid loss of cortical and trabecular bone mass Clinically, this progressive reduction in BMD significantly elevates the risk of osteopenia, osteoporosis, and fragility fractures, particularly within the lumbar spine and hip

This hormone deficiency markedly upregulates osteoclastic bone resorption relative to osteoblastic bone formation, resulting in accelerated microarchitectural deterioration and rapid loss of cortical and trabecular bone mass

Clinically, this progressive reduction in BMD significantly elevates the risk of osteopenia, osteoporosis, and fragility fractures, particularly within the lumbar spine and hip